Thus, differences in HIF-2α activity or HIF degrading prolylhydroxylases might influence the pulmonary artery hypertension counterregulating effects of hypoxemia, and thus alter patients’ outcome. The gene discussed is EPAS1; the disease is pulmonary arterial hypertension.